Isorhamnetin augments the anti-tumor effect of capeciatbine through the negative regulation of NF-κB signaling cascade in gastric cancer

Highlights • Regardless of rapid advances therapy for gastric cancer, it still remains second leading cause of cancer mortality. • Current drugs lack efficacy and yet are highly toxic. • Thus, novel pharmacological drugs that can overcome chemoresistance are needed. • We demonstrate that isorhamneti...

Full description

Saved in:
Bibliographic Details
Published in:Cancer letters 2015-07, Vol.363 (1), p.28-36
Main Authors: Manu, Kanjoormana A, Shanmugam, Muthu K, Ramachandran, Lalitha, Li, Feng, Siveen, Kodappully Sivaraman, Chinnathambi, Arunachalam, Zayed, M.E, Alharbi, Sulaiman Ali, Arfuso, Frank, Kumar, Alan Prem, Ahn, Kwang Seok, Sethi, Gautam
Format: Article
Language:English
Subjects:
Capecitabine
Gastric cancer
Hematology, Oncology and Palliative Medicine
Isorhamnetin
NF-κB
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Regardless of rapid advances therapy for gastric cancer, it still remains second leading cause of cancer mortality. • Current drugs lack efficacy and yet are highly toxic. • Thus, novel pharmacological drugs that can overcome chemoresistance are needed. • We demonstrate that isorhamnetin can significantly enhance effects of capecitabine against gastric cancer. • Thus, the findings of the present study can form the basis of a novel treatment regimen for gastric cancer patients.
ISSN:0304-3835
1872-7980
DOI:10.1016/j.canlet.2015.03.033